Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Debt Repayments (2016 - 2019)

Lineage Cell Therapeutics' Long-Term Debt Repayments history spans 5 years, with the latest figure at $18000.0 for Q2 2019.

  • For Q2 2019, Long-Term Debt Repayments fell 66.67% year-over-year to $18000.0; the TTM value through Dec 2019 reached $70000.0, down 58.58%, while the annual FY2019 figure was $70000.0, 30.69% down from the prior year.
  • Long-Term Debt Repayments reached $18000.0 in Q2 2019 per LCTX's latest filing, down from $52000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $97000.0 in Q1 2018 to a low of $17000.0 in Q1 2016.
  • Average Long-Term Debt Repayments over 5 years is $40272.7, with a median of $31000.0 recorded in 2017.
  • Peak YoY movement for Long-Term Debt Repayments: surged 212.9% in 2018, then tumbled 66.67% in 2019.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $28000.0 in 2015, then soared by 46.43% to $41000.0 in 2016, then tumbled by 56.1% to $18000.0 in 2017, then skyrocketed by 200.0% to $54000.0 in 2018, then crashed by 66.67% to $18000.0 in 2019.
  • Per Business Quant, the three most recent readings for LCTX's Long-Term Debt Repayments are $18000.0 (Q2 2019), $52000.0 (Q1 2019), and $54000.0 (Q2 2018).